Eslicarbazepine Acetate Tablet
Product Images NDC 59746-718

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 59746-718). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

200-30s (200 30s)

This is information about Eslicarbazepine acetate tablets, with a strength of 200 mg per tablet. The usual dosage instructions can be found in the package insert. The tablets are to be stored at a temperature between 20°C to 25°C (68 to 77°F). It is important to keep the container tightly closed and out of reach of children. The details include the manufacturer, Subilant Cadista Pharmaceuticals Inc., located in Yardley, PA, USA. The package contains 30 tablets. The Global Trade Item Number (GTIN), Lot No., and Expiration Date are also provided for identification and tracking purposes.*

FDA Label Image

400-30s (400 30s)

This text provides information about Eslicarbazepine Acetate Tablets, each containing 400mg of the active ingredient. The usual dosage is once a day. The tablets should be stored at controlled room temperature and kept out of reach of children. Pharmacists should provide the accompanying medication guide to each patient. Batch details like GTIN, Lot No., Exp date, and SINZ are also mentioned, with the reminder that variable batch details will be printed during final packing for commercialization.*

FDA Label Image

600-60s (600 60s)

This text appears to be a pharmaceutical label for Eslicarbazepine Acetate tablets, with dosage information and storage instructions. The medication is manufactured in India by Jubilant Cadista Pharmaceuticals and should be stored at temperatures between 15°C to 30°C. It contains 60 tablets per bottle and comes with a Medication Guide to be provided to each patient by the pharmacist. The package includes a unique NDC code for identification purposes. Additionally, there are batch details like Lot No. and GTIN provided for tracking and quality control purposes.*

FDA Label Image

800-30s (800 30s)

The text mentions a medication labeled with NDC 59746-720-30 for a specific dosage form. It also provides details such as the number of tablets per bottle, dosage information, a reminder to dispense with the accompanying Medication Guide, and instructions for pharmacists. Additional details include batch information, expiration date, and a note about batch details being printed during final packing.*

FDA Label Image

Figure1 (Fig01)

This text provides information on recommended dose adjustments for eslicarbazepine based on age, gender, hepatic impairment, and renal impairment. The recommended changes in dose due to these factors are detailed, along with fold change and confidence intervals. The text suggests that dose reduction is recommended for certain levels of hepatic and renal impairment. Overall, it advises on the necessity for dose adjustments or reductions based on specific patient characteristics to ensure optimal medication management.*

FDA Label Image

Figure2 (Fig02)

FDA Label Image

Figure04 (Fig04)

This text provides information on the KM estimate of exit rate and the dosage of Eslicarbazepine acetate tablets. It includes data for two different dosages (1,200 mg and 1,600 mg) along with the number of cases (N=54) and references to Study 1 and Study 2. This information can be useful for evaluating the effectiveness and safety of Eslicarbazepine acetate tablets at different dosages.*

FDA Label Image

Figure05 (Fig05)

FDA Label Image

Figure3a (Fig3a)

This text provides information about the change in various antiepileptic drugs (AEDs) including Carbamazepine, Gabapentin, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Topiramate, and Valproate. It also mentions the fold change and 90% confidence intervals for these drugs. The recommendations include potential dose adjustments and monitoring of plasma phenytoin concentration. Additionally, it suggests potential pharmacodynamic interactions with other drugs.*

FDA Label Image

Figure3b (Fig3b)

This text provides information on changes in various medications such as Digoxin, Metformin, Statins (Simvastatin, Rosuvastatin), Oral Contraceptives (Ethinylestradiol, Levonorgestrel), and Warfarin (S-Warfarin, R-Warfarin), including fold change and 90% CI. Recommendations include adjusting the dose of simvastatin or rosuvastatin in case of a clinically significant change in lipids, using additional or alternative non-hormonal birth control with oral contraceptives, and monitoring patients to maintain INR levels with Warfarin.*

FDA Label Image

Imprint (Imprint)

FDA Label Image

Imprint1 (Imprint1)

FDA Label Image

Structuralformula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.